StockNews.AI
VEEV
StockNews.AI
112 days

Announcing Veeva AI

1. Veeva AI initiative aims to enhance productivity in life sciences. 2. AI Agents and Shortcuts will automate tasks across Veeva applications. 3. Veeva AI is LLM agnostic, providing flexibility in model usage. 4. Initial release is planned for December 2025 with a subscription model. 5. CEO emphasizes AI's role in speeding up treatment delivery for patients.

7m saved
Insight
Article

FAQ

Why Bullish?

The introduction of Veeva AI could significantly enhance productivity in life sciences, mirroring past tech innovations in healthcare that positively influenced company valuations. For example, similar AI initiatives in other sectors led to productivity boosts and stock price increases.

How important is it?

The article details a major product initiative that could revolutionize Veeva's operations and market positioning, indicating a strong potential for long-term revenue growth and competitive advantage.

Why Long Term?

The full impact of Veeva AI won't materialize until its release in 2025, aligning with the rollout strategies of other major tech upgrades that typically see gradual adoption and long-term growth in stock prices thereafter.

Related Companies

VRTXBMRNSNYABT
Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial , /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI, a major new initiative that adds AI to the Veeva Vault Platform and Veeva applications to help life sciences companies automate tasks and improve employee productivity using AI Agents and AI Shortcuts. Veeva AI provides a fast and efficient way to introduce application-specific AI Agents based on large language models (LLMs) into existing Veeva applications and enable end users with AI Shortcuts. Veeva AI will work in all Veeva applications across all major areas, including clinical, regulatory, safety, quality, medical, and commercial. Veeva AI Agents can be deployed quickly with high impact because they understand the Veeva application context, have application-specific prompts and safeguards, and have direct, secure access to Veeva application data, documents, and workflows. Customers can configure and extend Veeva-delivered AI Agents and build custom AI Agents to address company-specific use cases. AI Agents can be used through a chatbot user interface or called via the AI API. Veeva AI Shortcuts empower end users with the ability to easily set up personal AI-powered automations to accomplish frequent user-specific tasks such as helping with workflows, generating insights, or researching a topic. "GenAI is a new computing paradigm that will significantly increase productivity for knowledge workers," said Veeva CEO Peter Gassner. "Core applications give you structured data, business rules and workflow. They execute with the speed, consistency, and scale we expect from computers. GenAI brings the more human-like ability to derive answers and insights from ambiguous situations that deal with language, context, and broad-based knowledge. Core applications and GenAI working seamlessly together will bring significant productivity gains." Veeva AI is LLM agnostic and will support most major large language models. Customers may use a Veeva-supplied LLM or configure Veeva AI to use a customer-specific LLM. Regardless of deployment or which LLM is used by a customer, Veeva AI keeps customer data secure for each customer. "Our customers depend on Veeva applications for some of their most critical industry-specific processes from clinical to commercial. They want to use AI to improve productivity and ultimately get treatments to patients faster," said CEO Peter Gassner. "Adding Veeva AI to our core applications will help make AI simple, secure, and compliant for life sciences companies of all sizes." The first release of Veeva AI is planned for December 2025 and will be licensed at the Vault level with a simple and reasonable subscription fee to encourage industry adoption that is both broad and thoughtful. About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov. Contact: Maria ScurryVeeva Systems781-366-7617[email protected] SOURCE Veeva Systems WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News